# Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

> **NCT03568916** · — · COMPLETED · sponsor: **Canadian Network for Observational Drug Effect Studies, CNODES** · enrollment: 227579 (actual)

## Conditions studied

- Atrial Fibrillation
- Ischemic Stroke
- Systemic Embolization
- Major Bleed
- Myocardial Infarction
- All-cause Mortality

## Interventions

- **DRUG:** Apixaban (ATC B01AF02)
- **DRUG:** Dabigatran (ATC B01AE07)
- **DRUG:** Rivaroxaban (ATC B01AF01)

## Key facts

- **NCT ID:** NCT03568916
- **Lead sponsor:** Canadian Network for Observational Drug Effect Studies, CNODES
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 227579 (ACTUAL)
- **Last updated:** 2021-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568916, "Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03568916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*